Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seamus Kent

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Kidney International|April 22, 2019
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney diseaseIryna Schlackow, Seamus Kent, William Herrington, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 7, 2025
APPRAISE: A Tool for Appraising Potential for Bias in Real-World Evidence Studies on Medication Effectiveness or SafetyKatsiaryna Bykov, Ashley Jaksa, Jennifer L Lund, et al.
Journal of Comparative Effectiveness Research|July 19, 2021
The use of nonrandomized evidence to estimate treatment effects in health technology assessmentSeamus Kent, Maximilian Salcher-Konrad, Stefania Boccia, et al.
Heart (British Cardiac Society)|August 7, 2017
A policy model of cardiovascular disease in moderate-to-advanced chronic kidney diseaseIryna Schlackow, Seamus Kent, William Herrington, et al.
BMC Nephrology|May 1, 2015
What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?Seamus Kent, Iryna Schlackow, Jingky Lozano-Kühne, et al.
BMJ Open|October 17, 2022
Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort studyAshley Jaksa, Liza Gibbs, Seamus Kent, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 13, 2024
Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task ForceRachael L Fleurence, Seamus Kent, Blythe Adamson, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 25, 2015
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)Borislava Mihaylova, Iryna Schlackow, William Herrington, et al.
Health Technology Assessment (Winchester, England)|May 6, 2020
Total versus partial knee replacement in patients with medial compartment knee osteoarthritis: the TOPKAT RCTDavid J Beard, Loretta J Davies, Jonathan A Cook, et al.
Lancet (London, England)|July 22, 2019
The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trialDavid J Beard, Loretta J Davies, Jonathan A Cook, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Kidney International|April 22, 2019
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney diseaseIryna Schlackow, Seamus Kent, William Herrington, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 7, 2025
APPRAISE: A Tool for Appraising Potential for Bias in Real-World Evidence Studies on Medication Effectiveness or SafetyKatsiaryna Bykov, Ashley Jaksa, Jennifer L Lund, et al.
Journal of Comparative Effectiveness Research|July 19, 2021
The use of nonrandomized evidence to estimate treatment effects in health technology assessmentSeamus Kent, Maximilian Salcher-Konrad, Stefania Boccia, et al.
Heart (British Cardiac Society)|August 7, 2017
A policy model of cardiovascular disease in moderate-to-advanced chronic kidney diseaseIryna Schlackow, Seamus Kent, William Herrington, et al.
BMC Nephrology|May 1, 2015
What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?Seamus Kent, Iryna Schlackow, Jingky Lozano-Kühne, et al.
BMJ Open|October 17, 2022
Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort studyAshley Jaksa, Liza Gibbs, Seamus Kent, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 13, 2024
Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task ForceRachael L Fleurence, Seamus Kent, Blythe Adamson, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 25, 2015
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)Borislava Mihaylova, Iryna Schlackow, William Herrington, et al.
Health Technology Assessment (Winchester, England)|May 6, 2020
Total versus partial knee replacement in patients with medial compartment knee osteoarthritis: the TOPKAT RCTDavid J Beard, Loretta J Davies, Jonathan A Cook, et al.
Lancet (London, England)|July 22, 2019
The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trialDavid J Beard, Loretta J Davies, Jonathan A Cook, et al.
Pageof 4